Skip to content
value.today

Genoa Pharmaceuticals, Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2011
Total raised
$245 M
4 rounds on record
Latest round
$189 M
Sep 2023
First round on record
Oct 2011
Today
Went public
See the company page

Genoa Pharmaceuticals, Inc. is listed today as Avalyn Pharma Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genoa Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2023$189 MNo. 4$50 to $250 million

Genoa Pharmaceuticals, Inc.: Raise no. 4, Sep 2023

Investors in this round

26 investors had bought by the notice of Oct 10, 2023: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Genoa Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$189 M of $189 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lyn Baranowski · Executive Officer, Director
  • Cassandra Gianna Luca · Director
  • Jill Gianna Carroll · Director
  • Jonathan Leff · Director
  • Ketan Patel · Director
  • Niall O'Donnell · Director
  • Peter Moldt · Director
  • Tiba Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lyn Baranowski, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 10, 2023. Read the notice at the SEC.

equitySEC
Apr 2020$36 MNo. 3$10 to $50 million

Genoa Pharmaceuticals, Inc.: Raise no. 3, Apr 2020

Investors in this round

8 investors had bought by the notice of May 8, 2020: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Genoa Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$36 M of $36 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Bruce Montgomery · Executive Officer, Director
  • Heather Bruce Preston · Director
  • Jonathan Bruce Leff · Director
  • Ketan Bruce Patel · Director
  • Niall Bruce O'Donnell · Director
  • Robert Bruce Mittendorff · Director
  • Sofia Bruce Ioannidou · Director
  • Tiba Bruce Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nancy McKinley, VP, Finance. Source: SEC Form D, newest notice filed May 8, 2020. Read the notice at the SEC.

equitySEC
Mar 2017$18 MNo. 2$10 to $50 million

Genoa Pharmaceuticals, Inc.: Raise no. 2, Mar 2017

Investors in this round

46 investors had bought by the notice of May 24, 2017: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Genoa Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $65 M offered; $47 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce W. Montgomery, M.D. · Director, Executive Officer
  • Mark W. Surber, Ph.D. · Executive Officer
  • Heather W. Preston · Director
  • Jonathan W. Leff, M.D. · Director
  • Ketan W. Patel · Director
  • Naveed W. Siddiqi · Director
  • Niall W. O'Donnell · Director
  • Tiba W. Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark W. Surber, Ph.D., Secretary. Source: SEC Form D and 1 amendment, newest notice filed May 24, 2017. Read the notice at the SEC.

equitySEC
Oct 2011$2 MNo. 1$2 to $10 million

Genoa Pharmaceuticals, Inc.: Raise no. 1, Oct 2011

Investors in this round

41 investors had bought by the notice of Aug 12, 2015: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Genoa Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$1
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark W. Surber, Ph.D. · Executive Officer, Director
  • Richard G. Vincent · Executive Officer
  • Daniel D. Burgess · Director
  • Michael J. Kamdar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark W. Surber, Ph.D., President and Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Aug 12, 2015. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genoa Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2023).

    SEC Form D · Oct 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2023

That is all the official record says: Genoa Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Genoa Pharmaceuticals, Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Genoa Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Fmr LLCFund or asset managernot statednot statedHeld Series A, B, C-1, C-2 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A, B, C-1, C-2 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
SR One Capital Management, LLCFund or asset managernot statednot statedHeld Series C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.Fund or asset managernot statednot statedHeld Series C-1 and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 46 investors.

Largest shareholders today

Institutions holding Avalyn Pharma Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genoa Pharmaceuticals, Inc.
NameRoleNamed in
Lyn BaranowskiExecutive officerOct 2023
A. Bruce MontgomeryExecutive officerMay 2020
Bruce W. Montgomery, M.D.Executive officerMay 2017
Mark W. Surber, Ph.D.Executive officerMay 2017
Bruce G. Montgomery, M.D.Executive officerMar 2017
Richard G. VincentExecutive officerMar 2017
Michael J. KamdarExecutive officerNov 2012
Cassandra Gianna LucaDirectorOct 2023
Jill Gianna CarrollDirectorOct 2023
Jonathan LeffDirectorOct 2023
Ketan PatelDirectorOct 2023
Lyn BaranowskiDirectorOct 2023
Niall O'DonnellDirectorOct 2023
Peter MoldtDirectorOct 2023
Tiba AynechiDirectorOct 2023
A. Bruce MontgomeryDirectorMay 2020
Heather Bruce PrestonDirectorMay 2020
Jonathan Bruce LeffDirectorMay 2020
Ketan Bruce PatelDirectorMay 2020
Niall Bruce O'DonnellDirectorMay 2020
Robert Bruce MittendorffDirectorMay 2020
Sofia Bruce IoannidouDirectorMay 2020
Tiba Bruce AynechiDirectorMay 2020
Bruce W. Montgomery, M.D.DirectorMay 2017
Heather W. PrestonDirectorMay 2017
Jonathan W. Leff, M.D.DirectorMay 2017
Ketan W. PatelDirectorMay 2017
Naveed W. SiddiqiDirectorMay 2017
Niall W. O'DonnellDirectorMay 2017
Tiba W. AynechiDirectorMay 2017
Bruce G. Montgomery, M.D.DirectorMar 2017
Jonathan G. Leff, M.D.DirectorMar 2017
Ketan G. PatelDirectorMar 2017
Naveed G. SiddiqiDirectorMar 2017
Niall G. O'DonnellDirectorMar 2017
Tiba G. AynechiDirectorMar 2017
Daniel D. BurgessDirectorAug 2015
Mark W. Surber, Ph.D.DirectorAug 2015
Michael J. KamdarDirectorAug 2015

Went public since 2026. Its SEC number is that of a company listed on a stock exchange.